Pronova BioPharma ASA : Discontinuation of reimbursement of Omacor in Spain
(Thomson Reuters ONE) -
Oslo, Norway, 24 August 2012: Pronova BioPharma (OSE: PRON.OL) yesterday
received notice that the Spanish Ministry of Health has decided, as part of a
general measure to reduce healthcare expenditure, to discontinue reimbursement
of Omacor with effect from 1 September. Pronova BioPharma and Grupo Ferrer, who
holds the exclusive license to Omacor in Spain, object to the decision and are
considering various actions to secure continued good access to Omacor for
Spanish patients.
The extent to which the decision will affect sales in Spain is unclear at
present. However, end-user sales in Spain represent less than 5 percent of sales
in the 8 major markets and the pharmaceutical product is launched in 60
countries.
About Pronova BioPharma:
Pronova is a global leader in research, development and manufacture of
lipid therapies derived from nature.
The group's first commercialised product, Omacor/Lovaza, is branded in a number
of countries (57) throughout Europe, Asia and in the USA. End-user sales has
grown rapidly in all international markets and the annual run rate at 31
December 2011 reached USD 1 380 million, according to IMS Health. The product is
the first EU- and FDA-approved omega 3-derived prescription drug.
Marketing and distribution of Pronova's key product is currently licensed to
both local and global pharmaceutical companies.
The company is in the process of developing several new, patentable lipid
derivatives. The most advanced lipid derived pharmaceutical programme is in the
area of combined dyslipidemia, the abnormal concentration of lipids and
lipoproteins in the blood, for which the company has a product, PRC-4016, in
clinical trials.
Pronova has also announced plans to enter the consumer healthcare and clinical
nutrition markets, enabling the company to further leverage its position as the
world's largest manufacturer of high grade omega-3 derived products.
Pronova's headquarters are located at Lysaker in Norway, while production takes
place at state-of-the-art manufacturing facilities at Sandefjord in Norway and
in Kalundborg, Denmark. The company's shares are listed on Oslo Børs with the
ticker code PRON. Additional information is available on www.pronova.com.
Contacts:
Hamed Brodersen,
VP Investor Relations and Communications
Tel: +47 40 46 81 10
This information is subject of the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Pronova BioPharma ASA via Thomson Reuters ONE
[HUG#1636051]
Unternehmensinformation / Kurzprofil:
Datum: 24.08.2012 - 08:00 Uhr
Sprache: Deutsch
News-ID 177437
Anzahl Zeichen: 3312
contact information:
Town:
Lysaker
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 131 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Pronova BioPharma ASA : Discontinuation of reimbursement of Omacor in Spain"
steht unter der journalistisch-redaktionellen Verantwortung von
Pronova BioPharma ASA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
